About this EventAdd to calendar
Please join this virtual talk with Scott Kraly, Professor of Psychology and Neuroscience.
Use of psychiatric medications has increased dramatically during recent decades: Approximately 35 million Americans are currently prescribed a medication to treat a diagnosed mental health problem. Is the increasingly common use of these psychoactive drugs warranted based upon scientific evidence?
Evidence-based treatment is guided by results from experiments assessing a drug’s efficacy, and anecdotal evidence acquired from clinical practice. The Food and Drug Administration (FDA) sets the standards for drug development, and regulates access to new medications. FDA-sanctioned Phase 3 clinical drug trials are methodologically rigorous experiments that assess efficacy and safety of new drugs. Results of these Phase 3 trials establish the gold-standard evidence to gain FDA approval to market a new medication (or a vaccine). Do Phase 3 trials provide convincing evidence that predicts that a newly marketed medication will be effective and well tolerated for you or me? What is not learned about a new medication from Phase 3 trials? What can be done to strengthen the scientific evidence base? How does legal off-label prescribing expand and delay development of an evidence base? Is a newer medication always better than an older one? In what important ways does post-marketing research improve upon the effectiveness of psychiatric medications?
4 people are interested in this event
Virtual weblink: https://zoom.us/j/99595774508 The webinar requires the password: nasc (all lowercase). The NASC colloquium link also requires you to have a registered Zoom account but does not require you to have a Colgate account. We are hoping these restrictions will make the talks as widely accessible as possible, while minimizing security risks.